Source: HealthDay News
As reported by HealthDay News, a new study published in Arthritis Care & Research finds that the antimalarial drug chloroquine may protect young women with lupus against metabolic syndrome. The National Heart, Lung and Blood Institute defines metabolic syndrome as “the name for a group of risk factors that raises your risk for heart disease and other health problems, such as diabetes and stroke.”
Led by Luciana F. Muniz, MD, from Faculdade de Medicina da Universidade de Sao Paulo in Brazil, researchers evaluated the frequency of metabolic syndrome and disease- or therapy-related factors in 103 premenopausal SLE patients (<40 years) and 35 healthy, premenopausal women of similar age.
Metabolic syndrome was significantly more common among those with lupus versus healthy volunteers. Chloroquine was less frequently used in lupus patients with metabolic syndrome, leading researchers to conclude that chloroquine has a protective effect on the prevalence of metabolic syndrome in these patients.